Ayala stock rises 16% on all-stock merger with Advaxis to focus on cancer drugs
seekingalpha.com
finance
2022-10-19 11:08:01

Maks_Lab Ayala Pharmaceuticals (NASDAQ:AYLA) and Advaxis (OTCQX:ADXS) are merging in an all stock transaction to focus on the development of cancer therapies. Under the agreement, each outstanding common share of Ayala will be converted into the right to receive common shares of Advaxis based on an exchange ratio. After the merger is completed, Ayala stockholders will own ~62.5% of the combined company, while the remaining ~37.5% will be held by Advaxis. The companies said Ayala will be delisted from Nasdaq and the combined company's common stock is expected to begin trading on the OTCQX at the effective time of the merger.
